A Real-World Study Assessing the Efficacy and Safety of Switching from Basal-Bolus Insulin Therapy to Once-Daily iGlarLixi in People with Type 2 Diabetes-Soli De-escalation

被引：0
|
作者：
Giorgino, Francesco
Lauand, Felipe, Sr.
Servera, Soraly
Li, Xuan
Taybani, Zoltan
Cheng, Alice Y. Y.
Fonseca, Vivian
Tebaibia, Amar
Anaforoglu, Inan
机构：
来源：
DIABETES | 2024年 / 73卷
关键词：
D O I：
10.2337/db24-1867-LB
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1867-LB
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Efficacy and safety of once-weekly insulin icodec vs once-daily basal insulin in type 2 diabetes by ethnicity and race: ONWARDS 1-5
    Lingvay, I.
    Bangsgaard, K. O.
    Desouza, C.
    Fragao-Marques, M.
    Navarria, A.
    Vianna, A.
    DIABETOLOGIA, 2024, 67 : S375 - S376
  • [42] Achievement of Glycemic Targets when Switching from Basal-Bolus Therapy to V-Go for Insulin Delivery in Type 2 Diabetes
    Hundal, Ripu S.
    Kowalyk, Stephan
    Cases, Jane
    Al-Karadsheh, Amer
    Wakim, Amanda P.
    Doyle, Melissa
    Sink, John H., II
    Spence, Adrienne
    Brewer, Jamie L.
    Nikkel, Carla C.
    DIABETES, 2018, 67
  • [43] Efficacy and Safety of iGlarLixi, Fixed-Ratio Combination of Insulin Glargine and Lixisenatide, Compared with Basal-Bolus Regimen in Patients with Type 2 Diabetes: Propensity Score Matched Analysis
    Tabak, Adam G.
    Anderson, John
    Aschner, Pablo
    Liu, Minzhi
    Saremi, Aramesh
    Stella, Peter
    Tinahones, Francisco J.
    Wysham, Carol
    Meier, Juris J.
    DIABETES THERAPY, 2020, 11 (01) : 305 - 318
  • [44] Efficacy and Safety of iGlarLixi, Fixed-Ratio Combination of Insulin Glargine and Lixisenatide, Compared with Basal-Bolus Regimen in Patients with Type 2 Diabetes: Propensity Score Matched Analysis
    Ádám G. Tabák
    John Anderson
    Pablo Aschner
    Minzhi Liu
    Aramesh Saremi
    Peter Stella
    Francisco J. Tinahones
    Carol Wysham
    Juris J. Meier
    Diabetes Therapy, 2020, 11 : 305 - 318
  • [45] Basal-Bolus vs. Premixed Insulin Regimen in Type 2 Diabetes: Comparison of Clinical Outcomes from Randomised Controlled Trials and Real-World Data
    Anyanwagu, Uchenna C.
    Mamza, Jil B.
    Donnelly, Richard
    Idris, Iskandar
    DIABETES, 2017, 66 : A259 - A259
  • [46] Switching from basal-bolus therapy with NPH insulin to basal-bolus therapy with the analog insulin detemir improves glycemic control and reduces hypoglycemic episodes, without weight gain, in type 1 and type 2 diabetes patients: Results from German subgroup of the PREDICTIVE study
    Ruhnau, Klaus-Juergen
    Hansen, Jes B.
    Dornhorst, Anne
    DIABETES, 2006, 55 : A133 - A133
  • [47] Safety and efficacy of insulin detemir basal-bolus therapy in type 1 diabetes patients:: 14-week data from the European cohort of the PREDICTIVE study
    Dornhorst, Anne
    Lueddeke, Hans-Joachim
    Honka, Marek
    Ackermann, Ralf W.
    Merilaeinen, Markus
    Gailwitz, Baptist
    Sreenan, Seamus
    CURRENT MEDICAL RESEARCH AND OPINION, 2008, 24 (02) : 369 - 376
  • [48] Efficacy and Safety of Intensive Versus Nonintensive Supplemental Insulin With a Basal-Bolus Insulin Regimen in Hospitalized Patients With Type 2 Diabetes: A Randomized Clinical Study
    Vellanki, Priyathama
    Cardona, Saumeth
    Galindo, Rodolfo J.
    Urrutia, Maria A.
    Pasquel, Francisco J.
    Davis, Georgia M.
    Fayfman, Maya
    Migdal, Alexandra
    Peng, Limin
    Umpierrez, Guillermo E.
    DIABETES CARE, 2022, 45 (10) : 2217 - 2223
  • [49] iGlarLixi vs. Premixed Insulin Initiation in Adults with Type 2 Diabetes (T2D) Advancing from Basal Insulin (BI) Therapy: SoliComplex Real-World Study
    Lajara, Rosemarie
    Heller, Caroline
    Pantalone, Kevin M.
    Lew, Elisheva
    Li, Xuan
    Dex, Terry A.
    Kilpatrick, Rachel
    DIABETES, 2022, 71
  • [50] Real-world safety and effectiveness of iGlarLixi in people with type 2 diabetes who fast during Ramadan: The SoliRam observational study
    Hassanein, Mohamed
    Malek, Rachid
    Shaltout, Inass
    Sahay, Rakesh Kumar
    Buyukbese, Mehmet Akif
    Djaballah, Khier
    Pilorget, Valerie
    Coudert, Mathieu
    Al Sifri, Saud
    DIABETES & METABOLIC SYNDROME-CLINICAL RESEARCH & REVIEWS, 2023, 17 (02)
12345